Please use this identifier to cite or link to this item:
Title: Impact of PCSK9 inhibitors in glycaemic control and new-onset diabetes
Authors: González Lleó, Ana María 
Sánchez Hernández, Rosa María 
Plana, Núria
Ibarretxe, Daiana
Rehues, Pere
Ribalta, Josep
Llop, Dídac
Wägner, Anna Maria Claudia 
Masana, Lluís
Boronat Cortés, Mauro 
UNESCO Clasification: 32 Ciencias médicas
320501 Cardiología
3209 Farmacología
Keywords: Familial Hypercholesterolemia
New-Onset Diabetes Mellitus
Pcsk9 Inhibitors
Prediabetes, et al
Issue Date: 2024
Journal: Cardiovascular Diabetology 
Abstract: Background: The diabetogenic effect of statins has been well established by clinical trials, Mendelian randomisation studies and meta-analyses. According to large clinical trials, PCSK9 inhibitors (PCSK9i) have no deleterious impact on glucose metabolism. However, few real-life studies have yet evaluated the long-term effects of these drugs on glucose homeostasis and their impact on new-onset diabetes (NODM). Methods: We studied 218 patients treated with either alirocumab or evolocumab (70% with familial hypercholesterolemia) for at least three years (PCSK9iG). We studied the NODM rate in the nondiabetic group at baseline (168) and overall glucose metabolism control in the whole group. Incidental DM was compared with two groups. The first was a propensity score matching (PSM)-selected group (n = 168) from the database of patients attending the Reus lipid unit (Metbank, n = 745) who were not on PCSK9i (PSMG). The second was a subgroup with a similar age range (n = 563) of the study (Spanish prospective study on diabetes development n = 5072) (D@G). The incidence was reported as the percentage of NODM cases per year. Results: The fasting glucose (FG) level of the subjects with normoglycaemia at baseline increased from 91 (86-95.5) to 93 (87–101) mg/dL (p = 0.014). There were 14 NODM cases in the PCSK9i group (2.6%/y), all among people with prediabetes at baseline. The incidence of NODM in PSMG and D@G was 1.8%/y (p = 0.69 compared with the PCSK9iG). The incidence among the subjects with prediabetes was 5.1%/y in the PCSK9iG, 4.8%/y in the PSMG and 3.9%/y in the D@G (p = 0.922 and p = 0.682, respectively). In the multivariate analysis, only the FG level was associated with the development of NODM in the PCSK9iG (OR 1.1; 95% CI: 1.0-1.3; p = 0.027). Neither FG nor A1c levels changed significantly in patients with DM at baseline. Conclusion: A nonsignificant increase in NODM occurred in the PCSK9iG, particularly in patients with prediabetes, compared with the PSMG and D@G groups. Baseline FG levels were the main variable associated with the development of DM. In the subjects who had DM at baseline, glucose control did not change. The impact of PCSK9i on glucose metabolism should not be of concern when prescribing these therapies.
ISSN: 1475-2840
DOI: 10.1186/s12933-023-02077-y
Source: Cardiovascular Diabetology [EISSN 1475-2840],v. 23 (1), p.4, (Enero 2024)
Appears in Collections:Artículos
Adobe PDF (1,08 MB)
Show full item record

Google ScholarTM




Export metadata

Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.